NOTE ON THE STATUS OF MEMBERSHIP OF THE
JOINT COORDINATING BOARD (JCB) AS AT 1 JANUARY 2025
AND MECHANISMS FOR SELECTION / RE-SELECTION OF MEMBERS

I. COMPOSITION OF THE JCB
(Extracted from the TDR Memorandum of Understanding - Paragraph 2.2)

(a) MEMBERS

The JCB shall consist of 28 members from among the Cooperating Parties as follows:

2.2.1 Twelve representatives from the governments contributing to the Special Programme Resources, selected by the contributors to the Special Programme. Each such government representative shall serve as representative of his/her government and may also serve as representative of a constituency established by governments under this membership category. Each constituency will develop its own procedure to designate its representative to the Board. In the event a government intends to serve on the Board also as representative of a constituency, it shall indicate this in its application for membership, it being understood that each government participating in that constituency shall be entitled to rotate as the representative of that constituency at any session of the JCB.

2.2.2 Six government representatives selected by the WHO Regional Committees from among those countries directly affected by the diseases dealt with by the Special Programme, or from among those providing technical or scientific support to the Special Programme.

2.2.3 Six members, designated by the JCB itself, from among the remaining Cooperating Parties.

2.2.4 The four co-sponsors of the Special Programme.

Members of the JCB shall serve for a period of four years and may be reappointed.

(b) OBSERVERS

Other Cooperating Parties may, at their request, be represented as observers upon approval by the JCB.
II. STATUS AS AT 1 JANUARY 2025

(a) MEMBERS SELECTED BY THE CONTRIBUTORS TO THE SPECIAL PROGRAMME RESOURCES (under paragraph 2.2.1 of the Memorandum of Understanding)

No vacancies will occur on 1 January 2025.

The Governments of Malaysia, Mexico and Switzerland, the constituency of the Governments of Germany and Luxembourg, the constituency of the Governments of India and Thailand, the constituency of the Governments of Panama and Spain, and the constituency of the Governments of the United Kingdom of Great Britain and Northern Ireland and the United States of America, are members until 31 December 2025. The Governments of Belgium, China, Japan, Nigeria and Sweden are members until 31 December 2026.

As no vacancies will occur from 1 January 2025 under paragraph 2.2.1 of the Memorandum of Understanding, it will not be necessary for the resource contributors to select any new members under this category.

(b) MEMBERS SELECTED BY THE WHO REGIONAL COMMITTEES (under paragraph 2.2.2 of the Memorandum of Understanding)

No vacancies will occur on 1 January 2025.

(i) African Region
    Equatorial Guinea is a member until 31 December 2026.

(ii) American Region
    Guatemala is a member until 31 December 2026.

(iii) Eastern Mediterranean Region
    Morocco is a member until 31 December 2026.

(iv) European Region
    Kyrgyzstan is a member until 31 December 2026.

(v) South-East Asian Region
    Bangladesh is a member until 31 December 2026.

(vi) Western Pacific Region
    The Republic of Korea is a member until 31 December 2026.
MEMBERS SELECTED BY THE JCB ITSELF
(under paragraph 2.2.3 of the Memorandum of Understanding)

No vacancies will occur on 1 January 2025.

The Governments of Burkina Faso and Zambia, and the Drugs for Neglected Diseases initiative and Fiocruz, are members until 31 December 2025. The Governments of Cuba and Sri Lanka are members until 31 December 2027.

As no vacancies will occur from 1 January 2025 under paragraph 2.2.3 of the Memorandum of Understanding, it will not be necessary for the JCB to select any new members under this category at its forty-seventh session.

III. MECHANISMS FOR OBTAINING OBSERVER STATUS AT JCB SESSIONS

Requests for observer status should be sent to the Special Programme Coordinator¹, WHO, Geneva, at least 30 days (13 May 2024) before the JCB session. (Observers attend sessions of the JCB at their own expense.)

¹ Dr Jeremy Farrar, WHO Chief Scientist